Dysplastic Nevus Syndrome Clinical Trial
Official title:
Phase I/II Evaluation of Topical Application of 20% Betulinic Acid Ointment in the Treatment of Dysplastic Nevi With Moderate to Severe Dysplasia
The purpose of this study is to evaluate the safety and effectiveness of an experimental 20% betulinic acid ointment (BA ointment) as a treatment for dysplastic nevi with the potential to transform into melanoma.
Approximately 200 patients may be enrolled and screened in order to find twenty-eight (28) patients who qualify to be involved in this research at UIC. Dysplastic melanocytic nevus (DMN) is a histopathologic term implying a disordered proliferation of melanocytes associated with discontinuous and variable cellular atypia. DMN is graded into mild, moderate, and severe based on standard histological criteria. DMN is considered to be a likely precursor for melanoma, and individuals with DMN often have multiple instances of it scattered over their trunk and extremities. For this study, only DMN where the dysplasia is either moderate or severe will be included. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04688749 -
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
|
||
Recruiting |
NCT00040352 -
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
|
||
Recruiting |
NCT04353050 -
Atypical MOLes and Melanoma Early Detection Study (MoleMed)
|
N/A |